BACKGROUND: Metabolic function is regulated by the interplay of central and peripheral factors that ultimately regulate food intake (FI) and energy expenditure. The tachykinin substance P (SP) has been identified as a novel regulator of energy balance, however, the mechanisms underlying this effect are ill-defined and conflicting data regarding the role of SP on FI have been reported by different groups. OBJECTIVE: To further characterize the metabolic role of the Tac1 gene products (SP and neurokinin A) in mice through a series of genetic, metabolic and behavioral studies in Tac1-deficient mice.
INTRODUCTION
Tac1 encodes the tachykinins substance P (SP) and neurokinin A. 1 SP is widely distributed in the brain and has been involved in a number of neurological processes such as nociception, anxiety or sleep disturbances. 1 In addition, we and others have documented the role of SP in the central control of the gonadotropic axis by stimulating, at least in part, Kiss1 neurons. [2] [3] [4] This action is also shared by neurokinin B, the other member of the tachykinin family of peptides. Numerous studies have characterized the role of neurokinin B in the control of GnRH release, including its action as a conveyor of the metabolic status to the central nodes that regulate reproduction. [5] [6] [7] Reproduction and metabolism are very tightly interconnected, 8 where reproduction is often halted during periods of energy deficiency as a mechanism to optimize chances of survival of the organism. Thus, neuropeptides involved in the control of metabolism often participate in the control of fertility. In this context, a metabolic role of SP has also been revealed in recent years. Studies by Karagiannides et al. 9 documented that the blockade of SP signaling leads to the decrease of body weight (BW) in diet-induced obese mice and leptin-deficient mice, as well as to the increase in insulin sensitivity. Recently, Trivedi et al. 10 identified the products of the Tac1 gene as mediators of the action of ghrelin in the regulation of energy balance by controlling the levels of adiposity. While there is increasing evidence supporting the role of SP in the control of energy balance, a detailed characterization of the metabolic phenotype of the absence of Tac1 and the mechanisms of action underlying the effect of SP is missing. The studies mentioned above have documented controversial data regarding the orexigenic action of SP. In some cases, it has been described to induce food intake (FI), while no action or even inhibition of FI has been described in others. [9] [10] [11] Whether this is due to the differences in the animal model (mouse vs rat) or to the dose/route of administration remains to be deciphered and evidences the need for further research to clarify this role. Furthermore, the first studies using Tac1 null mice did not show any difference in body size compared to controls. 9 However, our present data contradict that study and clearly evidence a metabolic phenotype in these animals, including significantly lower BW in all studied conditions during adulthood.
Therefore, in this study we aim to further characterize the role of SP and neurokinin A in the control of energy balance through a number of pharmacological, behavioral and genetic studies using the Tac1 knockout mouse as our animal model, including the involvement of Tac1 in the etiology of hepatic steatosis and metabolic syndrome.
RESEARCH DESIGN AND METHODS

Animals
Tac1
−/− and ob/ob mice were purchased at The Jackson Laboratories (Bar Harbor, ME, USA) and maintained at Harvard Medical School in a 12:12 light-dark cycle. Time of lights on (0700 hours) is considered Zeitgeber 0. Animals were housed at 21-22°C. All animal care and procedures were in accordance with the guidelines of the Harvard University Institutional Animal Care and Use Committee.
Metabolic measurements
Adult 12-to 20-week-old mice were housed 3-4 mice per cage and fed regular chow (LabDiet, St Louis, MO, USA #5053) or highfat diet (HFD; LabDiet #58Y1; 61% fat, 21% carbohydrates and 18% proteins). Insulin and leptin were measured in the morning (1000 hours) of the final day on HFD (day 16). For the glucose tolerance test, adult males (n = 6 per group) were fasted for 5 h before the test and injected intraperitoneally with 2 g kg − 1 glucose (Sigma Aldrich, St Louis, MO, USA), and glucose levels determined using a glucometer (Accu Chek, Indianapolis, IN, USA) by tail bleeds at 0, 20, 60 and 120 min.
Whole-body composition was determined by magnetic resonance imaging following the manufacturer's protocol before and after the Comprehensive Lab Animal Monitoring System study. For this study, male mice (n = 3 per group) were first left to acclimate to the metabolic cage for 24 h (START) and then monitored for 4 days fed a HFD (RE-START). Lights and temperature were kept as in their home cages. In the remaining experiments where FI was determined, food pellets were placed in small bowls and the amount of food remaining was subtracted from the previous determination.
Neutral lipid accumulation in the liver of double knockouts (DKOs) was determined using Oil Red 0 staining and ImageJ (imagej.nih.gov/ij/list.html, NIH, Bethesda, MD, USA) (investigator blinded to the group) as described elsewhere. 12 Gene expression determinations Total RNA was extracted from frozen tissue collected at Zeitgeber 3 using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) followed by chloroform/isopropanol extraction. RNA was quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Carlsbad, CA, USA) and 1 μg of RNA was reverse transcribed using Superscript III cDNA synthesis kit (Invitrogen). Quantitative realtime PCR assays were performed on an ABI Prism 7000 sequence detection system, and analyzed using ABI Prism 7000 SDS software (Applied Biosystems, Foster City, CA, USA). The cycling conditions were the following: 2 min incubation at 95°C (hot start), 45 amplification cycles (95°C for 30 s, 60°C for 30 s and 45 s at 75°C, with fluorescence detection at the end of each cycle), followed by melting curve of the amplified products obtained by ramped increase of the temperature from 55 to 95°C to confirm the presence of single amplification product per reaction. Information of specific primers in Supplementary Table S1 .
Hormone determination Leptin and insulin levels were measured using a Milliplex MAP immunoassay (mouse metabolic panel, Millipore Corporation, Billerica, MA, USA) in the Luminex 200 (BioRad, Hercules, CA, USA) following the manufacturer's protocol.
Statistical tests
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). Data are shown as mean ± s.e.m. and the significance level was set as P o 0.05. Differences were determined using a two-tailed unpaired Student's t-test or an analysis of variance test followed by Newman-Keuls or Tukey post hoc tests.
RESULTS
Tac1
− / − mice are leaner and resistant to HFD-induced obesity BW of male and female Tac1 −/− mice was monitored from 4 to 12 weeks of age. At week 5, BW of Tac1 −/− mice of both sexes started to deviate from their control littermates, becoming significantly leaner from 7-8 weeks of age onward (Figures 1a  and b) , despite having similar body lengths ( Figure 1c ). To stress the metabolic phenotype of these animals, adult males were subjected to HFD for 16 days. Proportionally, Tac1
−/− mice gained significantly less BW than littermate controls (Figure 1d ). Despite the 20% increase in BW observed in Tac1 −/− mice compared with their basal (pre-HFD) state and the significantly higher leptin levels at the end of the treatment (Figures 1d and e) , these animals did not develop the expected insulin resistance associated with HFD 13 at the end of the treatment, as seen in the control group (Figure 1f) . Also, Tac1 −/− mice had better glucose tolerance than the wild-type (WT) control mice (Figures 1g and h ), in keeping with previous reports, 9, 14 suggesting that SP induces insulin resistance.
Metabolic characterization of Tac1 null mice in the dark vs light phase To further explore their metabolic phenotype, adult male mice were subjected to a Comprehensive Lab Animal Monitoring System study for 4 days while fed a HFD. Body composition of these mice was determined by magnetic resonance imaging before and after the HFD. Given the baseline BW difference between control and Tac1 , was reduced during both phases in knockouts (Figures 2h and i ). RER and kcal h − 1 are indicators of the FI pattern. The blunted oscillations in RER and the overall lower heat production suggested a disruption in the amount and time that food was consumed. Indeed, an overall lower FI was seen in Tac1 (Figures 2j and k) . However, they ate more than controls during the day and less during the night (Figure 2l ), which was in keeping with the flattening of diurnal RER values, indicating continued food consumption during the day and consistent with the attenuation of the circadian feeding behavior. Moreover, despite the fact that the light phase is the period of lower activity in the mouse, Tac1 −/− mice showed even less activity than controls (Figure 2m ). Whether this is due to a further inhibition of the suprachiasmatic nucleus (SCN) mechanisms that control circadian activity 15 or to the fact that Tac1 −/− mice spent more time eating during this period cannot be determined and could contribute to the lower energy expenditure (Figures 2e and g ).
Expression of circadian genes in the absence of Tac1
The previous experiment revealed a differential behavioral pattern in Tac1 −/− mice compared with their WT controls, suggesting an alteration of the mechanisms that control circadian rhythms in these mice. Thus, we hypothesized that the absence of the Tac1 products would alter the expression of clock genes involved in the Tac1 controls food intake and metabolism CA Maguire et al control of these rhythmic patterns. Indeed, Tac1 −/− mice displayed significantly lower Cry1 and Cry2 levels in the preoptic area (which includes the SCN) at 1000 hours (Figure 3a )-when expression levels are otherwise maximal, 16 higher Per1 expression and a trend of lower Bmal1 expression in the mediobasal hypothalamus (where the main metabolic centers are located; Figure 3b) , and higher levels of Per1 and Per2 in the liver (Figure 3c ).
The expression of hypothalamic proopiomelanocortin and brown adipose tissue Ucp1 and Ucp2 is altered in the absence of Tac1 Tac1 −/− mice display an overall reduction in calorie intake (Figures 2j-l) . FI is determined by the interaction of hypothalamic neuropeptides that respond to peripheral indicators of fuel availability, for example, leptin, ghrelin or insulin. 17 Thus, we analyzed the gene expression of the FI regulators Agoutirelated peptide (Agrp), neuropeptide Y (Npy), proopiomelanocortin (Pomc), orexin (Hcrt1) and ghrelin receptor (Ghsr) in the mediobasal hypothalamus and observed that Tac1 −/− mice displayed a significant elevation in proopiomelanocortin expression (Figure 3d ).
In addition, brown adipose tissue (BAT) has an important role in energy homeostasis by increasing heat production. 18 In Tac1 ) in serum at the end of the HFD treatment (± s.e.m., n = 4 per group). Different letters indicate statistically different values (two-way ANOVA followed by Newman-Keuls post hoc test, P o0.05). (g) Glucose tolerance test (GTT) in adult males (n = 5-6 per group). *P o0.05, repeated measures two-way ANOVA and Bonferroni post hoc test. (h) Area under the curve (AUC) for glucose levels over 120 min. *Po 0.05 Student's t-test compared with its respective control. (Figure 3e ), despite the lack of Tac1 (or receptors for the Tac1 products) in the BAT (Figure 3f) , suggesting an indirect activation of the BAT.
Tac1 deficiency improves hepatic steatosis of obese (ob/ob) mice To further explore the role of Tac1 in the control of metabolism, we assessed the effect of Tac1 deletion in severely obese leptindeficient (ob/ob) mice. Ob/ob:Tac1 −/− (DKO) mice showed a modest, but significant, reduction of BW in females (but not in males) after 9 weeks (Figures 4a and b) . Of note, Tac1 expression (at least in the mediobasal hypothalamus) is not subject to regulation by leptin (Figure 4c) , suggesting that the action of Tac1 is independent of the action of leptin or limited to posttranscriptional processes. We next aimed to investigate whether the increase in insulin sensitivity and changes in the expression of circadian genes observed in our previous experiments in males lacking a functional Tac1 gene was enough to improve metabolic syndrome and liver steatosis (present in obese mice) in DKO males. Interestingly, DKO mice had significantly lower lipid content in the liver (Figures 4d and e) . In addition, they displayed significantly lower levels of the plasma triglyceride marker ApoA4 (Figure 4f ). These data indicate an improvement in liver fat accumulation and reduced circulating triglyceride levels compared to age-and, importantly, weight-matched ob/ob mice, indicating that the reduction of their liver steatosis is not (indirectly) due to changes in BW.
DISCUSSION
Recent studies have demonstrated a role of SP in the control of metabolism, [9] [10] [11] 14 but the mechanism of action of the orexigenic role of SP (or neurokinin A) requires further examination. Here we have expanded the characterization of this metabolic component of the Tac1 products and further described the metabolic phenotype of Tac1 null mice that was not documented in previous publications.
SP levels correlate with obesity in humans and rodents. 9, 19, 20 While disruption of SP/neurokinin 1R signaling had been linked to reduced FI, 9 conflicting studies had reported stimulation, no action or even inhibition of FI by SP. 9, 10, 14 Our studies have demonstrated that Tac1 −/− mice fed a regular chow diet display significantly lower BW in adulthood and gain significantly lower BW after 60% HFD treatment for 16 days. These latter results are consistent with previous studies by Karagiannides et al.
14 in the receptor-deficient Tacr1 −/− mice but contradict a different report ) (c, d) and VCO 2 (ml kg
) (e); RER (f, g); heat produced, indicated by kcal h − 1 (h, i); accumulated FI (j-l); and locomotor activity, indicated by total beam breaks (m) during the dark and light phases ( ± s.e.m., n = 3 per group). Different letters indicate statistically different values (two-way ANOVA followed by Newman-Keuls post hoc test, Po 0.05) (h). *P o0.05 Student's t-test. Tac1 controls food intake and metabolismby the same group in Tac1 −/− mice, where no changes in BW were detected after 45% HFD. 11 This discrepancy between both Tac1
−/− models may be derived from the different diet and/or length of the treatment. However, no characterization of the BW in Tac1 −/− mice under regular chow diet had been previously reported, so this cannot be compared between both models. Importantly, sex steroids also influence metabolic function through their anorectic action. 21 In this context, it is important to mention that while our previous studies have identified a reproductive impairment in male and female Tac1 −/− mice, this was limited to the timing of puberty onset (delayed) in both sexes and central induction of ovulation in the female. 4, 22 Adult WT and Tac1 −/− females displayed the same luteinizing hormone levels in the intact and ovariectomized states. 4 Similarly, adult WT and Tac1 −/− males displayed the same luteinizing hormone and testosterone levels. 22 These data exclude the possibility that different circulating levels of sex steroids could account for the metabolic phenotype describes in Tac1-deficient mice. Moreover, hypogonadism, at least in female rodents, leads to an increase in BW, 21 which is opposite to the phenotype observed in Tac1 −/− mice. Interestingly, our studies uncovered a potential role of SP in the control of circadian feeding behavior. Recent studies have provided evidence for the bidirectional interaction between diet and the diurnal pattern of feeding. 15, 23 Mice restrict their feeding mostly to the nocturnal phase of the day and restricting food to this phase prevents obesity in animals fed a HFD, 24 demonstrating the importance of the circadian feeding behavior. Nonetheless, the mechanisms that link environmental light cues to the regulation of feeding remain unknown. Interestingly, SP is present in the retina, optic nerve and SCN, and is involved in the transmission of photic information from the retina to the SCN. [25] [26] [27] [28] [29] [30] The SCN is the pacemaker of circadian oscillations. This hypothalamic nucleus holds transcriptional and translational feedback mechanisms that determine the alternation of circadian processes between the light and dark phases by regulating the expression of the clock genes, for example, Clock, Bmal1, Cry1, Cry2, Per1 and Per2. 23 However, how the SCN integrates the information on light cycles from the retina to synchronize circadian rhythms is unknown. The present studies suggest that Tac1 may be involved in the transmission of this information to the SCN to regulate feeding behavior in a murine model, and open the door for further research to uncover its mechanism of action. The absence of a functional Tac1 gene flattened the circadian RER oscillation as a consequence of higher FI during the light phase and lower during the dark phase compared with controls. The greater inhibition to seek food during the night led to an overall reduction of FI and therefore BW in Tac1 −/− animals, consistent with previous pharmacological studies where neurokinin 1R antagonists inhibited FI in mice. 9 Of note, HFD is known to disrupt feeding patterns in WT animals; 31 however, in our experiment (Figure 2 ) control WT animals fed a HFD retained their normal feeding behavior (mostly nocturnal), which excludes diet as the source of the disruption in the feeding rhythm in Tac1 −/− mice. Importantly, the disruption of the circadian clock machinery, namely Cry1/2, Per1/2, Clock and Bmal1 leads to metabolic diseases in mice. 23 We observed that at Zeitgeber 3, the absence of Tac1 reduced Cry1 and Cry2 expression in the preoptic area, where the SCN is located. In this vein, the resistance to gain BW of Tac1 −/− mice under a HFD replicates the phenotype of Cry1 −/− mice under the same diet-induced obesity protocol. 32 This supports the existence of a SP-Cry pathway in the control of energy balance. Furthermore, despite the unknown role of circadian genes in other tissues, Tac1
−/− mice displayed increased Per1 in the mediobasal hypothalamus, where the central metabolic regulators are located (for example, AgRP and proopiomelanocortin neurons) and increased Per1 and Per2 expression in the liver, probably as consequence of the altered feeding behavior. 33 Future studies will be aimed at determining the magnitude of the changes in the oscillation of these clock genes throughout the day in the absence of Tac1, as well as the neuroanatomical source of SP.
Importantly, these animals showed an increase in the melanocortin pathway, displaying higher proopiomelanocortin expression, which encodes the anorexigenic peptide α-Melanocytestimulating hormone, and a trend to lower AgRP levels. A recent characterization of the transcriptome of arcuate neurons documented the presence, albeit at low levels, of Tac1r, but not Tacr2, in proopiomelanocortin and AgRP neurons. 34 However, whether SP can modulate the action of proopiomelanocortin and/or AgRP neurons directly remains to be deciphered. Nonetheless, these data suggested that the overall reduction in FI observed in these mice may be due to the activation of the melanocortin pathway. Importantly, whether this reduction in FI leads, in turn, to further alteration in the expression of the circadian genes, remains to be deciphered.
Furthermore, to address whether the leaner phenotype of Tac1 knockout mice could also involve the activation of mechanisms of heat dissipation, we investigated the effect of SP absence on the activation of the thermogenic markers Ucp1, Ucp2 and Ucp3 in BAT. Indeed, we observed that Ucp1 and Ucp2 were significantly upregulated. The activation of BAT is a critical component in energy homeostasis and, therefore, a likely contributor to the leaner phenotype seen in Tac1 −/− mice. It is also possible that Tac1 − / − mice are more sensitive to a moderate cold stress (21-22°C) that leads to further activation of BAT in null animals. Paradoxically, these mice showed lower energy expenditure under HFD (Figure 2h ), probably due to the fact that a larger BW and higher leptin levels in WT mice under HFD (Figure 1e ) increased their energy expenditure 35 above the level of Tac1 − / − mice. However, neither Tac1 nor Tacr1 mRNA were detected in BAT (Figure 3f ). Interestingly, this may suggest a central action through the sympathetic nervous system, based on a previous study 36 that showed activation of BAT through an E 2 -dependent decrease in AMP-activated protein kinase (AMPK) at the central level. In this context, it has been demonstrated that SP can stimulate AMPK, 37 therefore, we can speculate that the lack of SP may lead to a decrease in AMPK and, therefore, to the activation of BAT (mimicking the E 2 effect).
Finally, we hypothesize that if the absence of SP activates the melanocortin pathway and heat dissipation, removing this gene from a model of severe obesity, for example, leptin deficiency (ob/ ob mice), would lead to an improvement of their metabolic phenotype. Previous studies had reported a robust decrease in BW in ob/ob mice after neurokinin 1R antagonist treatment. 9 Thus, we aimed to use a model of double Tac1 −/− and ob/ob knockouts (DKO) to address our hypothesis. We observed that female, but not male, DKO mice showed a modest but significant reduction of BW in comparison to ob/ob mice at the end of the study, suggesting that a portion of the obese phenotype, at least in obese female mice, may come from the effect of SP. Interestingly, Tac1 is highly enriched in LepRb neurons, 38 suggesting that leptin may inhibit the release of SP from leptin responsive neurons as part of its anorexic role. If this is true, the ablation of SP release in ob/ob mice may account for the decrease in BW observed (at least in females). Still, in males, despite the absence of a BW difference between DKO and ob/ob mice, DKO mice displayed a significant improvement in the triglyceride marker Apoa4 in the liver, as well as significantly reduced hepatic steatosis compared with ob/ob mice as seen by decreased lipid content.
In summary, the present results add further evidence for the role of SP in the control of FI, which may involve a role in the control of circadian feeding behavior and its interactions with the melanocortin system and the peripheral stimulation of energy expenditure through BAT activation. These data placed SP as a critical player in the development of metabolic diseases (for example, obesity, type 2 diabetes, hypertriglyceridemia and nonalcoholic steatohepatitis/nonalcoholic fatty liver disease), suggesting that SP blockade may serve as a novel therapeutic target for their treatment.
